Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
The Betterise website indicates that it joined Resilience in 2021. The product is currently positioned as “digital health” software designed to collect and analyze real-world data from patients at home, helping healthcare professionals conduct remote follow-up, detect relapse or treatment toxicity, and provide treatment education for patients. Its key use cases include oncology, cardiovascular care, and urology, with Resilience PRO focused on remote cancer care.
The product is built around three main capabilities. First, remote follow-up: continuously collecting patient data in home settings. Second, detection: using CE-marked algorithms to help healthcare teams identify relapse and treatment-related issues. Third, support and education: providing remote treatment education and support for patients. Its value as enterprise software is not general-purpose collaboration, but medical-grade functionality that complements hospital information systems. The website states that it can be used as a standalone web version within a few hours, can also be compatible with patient portals, and can connect with DPI/electronic medical record systems, reducing the need for hospitals to build duplicate tools.
Pricing information is limited. The site only offers demo requests and email contact, with no visible details on plans, per-bed/per-patient/institutional subscription models, free versions, or trials. Compliance is its strongest highlight: the product is described as a digital medical device, carries CE marking, has a manufacturer certified by GMED, is registered with ANSM and EUDAMED, and has a quality system involving ISO 13485. Security is aligned with PGSSI-S/ISO 27001, and data processing complies with RGPD/GDPR. These details are highly important for procurement by European healthcare institutions.
Its strengths are a clear healthcare-specific focus, relatively complete compliance credentials, and the ability to integrate with existing patient portals and electronic medical record systems. It is suitable for hospitals, specialty centers, and care teams managing oncology and other chronic or serious-disease patients outside the hospital. The weaknesses are limited commercial information: permissions, API documentation, SLA, implementation services, and localization capabilities are not disclosed. In addition, the Betterise brand has been integrated into Resilience, so buyers should confirm the current product line, contracting entity, and deployment boundaries before procurement.
The website does not provide information on access from China, payment options, or local compliance, and actual network connectivity is unknown. Because cross-border medical data transfer, medical device registration, and hospital information system integration all involve high requirements, Chinese organizations should not purchase it simply as a SaaS tool. They should focus on evaluating local regulations, data storage, and in-hospital interfaces. Alternative directions may include domestic hospital follow-up platforms, internet hospital systems, oncology patient management systems, or specialty follow-up modules from electronic medical record vendors.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on betterise.fr official site.
betterise.fr is an France Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach betterise.fr directly.